Literature DB >> 18374401

Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas.

Andrew J Li1, Daniel R Scoles, Klara U M Armstrong, Beth Y Karlan.   

Abstract

OBJECTIVE: Length of a polymorphic cytosine-adenine-guanine (CAG) repeat in the androgen receptor (AR) may inversely correlate with AR activity. We have identified an association between short AR allelotypes and decreased survival in women with epithelial ovarian cancer. We hypothesize short AR allelotypes promote aggressive ovarian cancer phenotype through modulation of epidermal growth factor receptor (EGFR) signaling.
METHODS: SKOV-3 cells were transfected with AR plasmids containing variable CAG repeat lengths, and AR activity was assessed through co-transfection with a luciferase plasmid. EGFR signaling was studied with Western blot analysis of EGFR, EGFR-p (phosphorylated), MAPK, and MAPK-p, and cellular proliferation examined by MTT assays. Data were analyzed using analysis of variance, Tukey-Kramer multiple comparison test, and Student's t test.
RESULTS: We confirmed AR allelotype length inversely correlates with AR activity in epithelial ovarian cells; a 2.5% decrease in luciferase-fold activation was seen with each CAG unit increase (p=0.0002). We observed inhibition of EGFR-p abundance with increasing abundance of transfected AR cDNA (89.2% and 39.9% for 3.0 and 6.0 mug, compared to 1.5 microg, p=0.03). After transfection with short (CAG=14), median (CAG=21), and long (CAG=24) AR allelotypes, an inverse correlation was identified between abundance of MAPK-p and CAG repeat length (p=0.002). Decrease in cellular abundance was also seen in cultures transfected with ARs of increasing CAG repeat length (p<0.0001).
CONCLUSIONS: These data identify an inhibitory action of AR on EGFR signaling, and support research investigating AR/EGFR antagonism in the treatment of ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374401     DOI: 10.1016/j.ygyno.2008.02.010

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  Revisiting the role of antiandrogen strategies in ovarian cancer.

Authors:  Dionysis Papadatos-Pastos; Konstantin J Dedes; Johann S de Bono; Stanley B Kaye
Journal:  Oncologist       Date:  2011-09-23

2.  Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion.

Authors:  Song Ling Poon; Gareth T Hammond; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2009-07-16

3.  PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.

Authors:  Mary T Galgano; Mark Conaway; Adam M Spencer; Bryce M Paschal; Henry F Frierson
Journal:  Hum Pathol       Date:  2009-05-07       Impact factor: 3.466

4.  Predicting time to ovarian carcinoma recurrence using protein markers.

Authors:  Ji-Yeon Yang; Kosuke Yoshihara; Kenichi Tanaka; Masayuki Hatae; Hideaki Masuzaki; Hiroaki Itamochi; Masashi Takano; Kimio Ushijima; Janos L Tanyi; George Coukos; Yiling Lu; Gordon B Mills; Roel G W Verhaak
Journal:  J Clin Invest       Date:  2013-08-15       Impact factor: 14.808

Review 5.  The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications.

Authors:  Haiyan Zhu; Xuejie Zhu; Lihong Zheng; Xiaoli Hu; LuZhe Sun; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-04-25

Review 6.  The Role of Androgen Receptor Signaling in Ovarian Cancer.

Authors:  Taichi Mizushima; Hiroshi Miyamoto
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

7.  Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).

Authors:  Susana Banerjee; Holly Tovey; Rebecca Bowen; Elizabeth Folkerd; Lucy Kilburn; Jennifer McLachlan; Marcia Hall; Nina Tunariu; Ayoma Attygalle; Joao Paulo Da Silveira Nogueira Lima; Sophie Perry; Peter Chatfield; Margaret Hills; Stan Kaye; Gert Attard; Mitch Dowsett; Judith M Bliss
Journal:  Ther Adv Med Oncol       Date:  2020-12-29       Impact factor: 8.168

8.  Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis.

Authors:  Keshav K Singh; Vanniarajan Ayyasamy; Kjerstin M Owens; Manika Sapru Koul; Marija Vujcic
Journal:  J Hum Genet       Date:  2009-07-24       Impact factor: 3.172

9.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

10.  Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.

Authors:  Kaijian Ling; Lupin Jiang; Shi Liang; Joseph Kwong; Leiyan Yang; Yudi Li; Qingchun Deng; Zhiqing Liang
Journal:  J Ovarian Res       Date:  2018-05-02       Impact factor: 4.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.